8-KEarnings & ResultsMaterial AgreementsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jan 15, 2009)

Filed January 15, 2009For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on January 15, 2009, primarily detailing an amendment to its lease agreements for its corporate headquarters and adjacent laboratory space. The leases, originally set to expire in 2010, have been extended to December 31, 2015, with options for two five-year extensions. This extension provides Vertex with long-term operational stability at its key Cambridge, Massachusetts facilities. The filing also references a press release issued on January 12, 2009, which provided preliminary financial information. This includes estimated net loss for 2008, aggregate stock-based compensation expense, restructuring expense, and the company's cash, cash equivalents, and marketable securities balance as of December 31, 2008. Investors should refer to the press release (Exhibit 99.1) for specific financial figures, as this 8-K only announces the existence of that release.

Key Highlights

  • 1Vertex Pharmaceuticals amended its leases for approximately 292,000 square feet of laboratory and office space at its Cambridge, MA headquarters and adjacent property.
  • 2The lease amendments extend the terms from their original 2010 expiration to December 31, 2015.
  • 3The amended leases include two options to extend for additional five-year terms, securing Vertex's presence at these locations through at least 2025.
  • 4The company entered into these agreements on January 12, 2009.
  • 5The filing references a press release issued on January 12, 2009, containing preliminary financial results for fiscal year 2008.
  • 6Key financial information in the press release includes estimated net loss, stock-based compensation, restructuring expenses, and year-end cash and marketable securities.
  • 7This 8-K filing focuses on material agreements and the announcement of financial results, not the detailed financial statements themselves.

Frequently Asked Questions

The lease amendments secure Vertex Pharmaceuticals' primary operational facilities in Cambridge, Massachusetts, for an extended period, through at least December 31, 2015, with options to renew for another ten years. This provides significant long-term stability and predictability for the company's research and development and administrative functions.

The specific financial results, including estimated net loss, stock-based compensation, restructuring expenses, and cash balances for 2008, are detailed in a press release dated January 12, 2009. This press release is attached as Exhibit 99.1 to this 8-K filing and is incorporated by reference.

No, this 8-K filing does not contain full audited financial statements. It announces the entry into material definitive agreements (lease amendments) and references a press release that provides preliminary financial information and estimates for the year ended December 31, 2008.

Vertex entered into amendments to its existing leases for its corporate headquarters and adjacent laboratory space located at 130 Waverly Street and 200 Sidney Street in Cambridge, Massachusetts. These amendments extend the lease terms significantly.